PharmaCyte Biotech
PMCB
PMCB
32 hedge funds and large institutions have $8.79M invested in PharmaCyte Biotech in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less capital invested
Capital invested by funds: $8.83M → $8.79M (-$36K)
95% less call options, than puts
Call options by funds: $100K | Put options by funds: $2.01M
Holders
32
Holding in Top 10
1
Calls
$100K
Puts
$2.01M
Top Buyers
| 1 | +$204K | |
| 2 | +$156K | |
| 3 | +$123K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$114K |
| 5 |
SC
Shay Capital
New York
|
+$85.2K |
Top Sellers
| 1 | -$480K | |
| 2 | -$141K | |
| 3 | -$97.3K | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$36.4K |
| 5 |
JPMorgan Chase & Co
New York
|
-$6K |